Kyntra Bio, Inc.
KYNB
$7.91
-$0.13-1.65%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -139.43% | 192.72% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -139.43% | 192.72% | |||
| Cost of Revenue | -41.54% | 54.68% | |||
| Gross Profit | -4.58% | -26.56% | |||
| SG&A Expenses | 58.07% | -19.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.24% | 18.51% | |||
| Operating Income | -27.31% | -2.05% | |||
| Income Before Tax | 179.12% | -3.57% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 179.13% | -3.57% | |||
| Earnings from Discontinued Operations | -- | -116.92% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 178.79% | -6.88% | |||
| EBIT | -27.31% | -2.05% | |||
| EBITDA | -27.33% | -2.06% | |||
| EPS Basic | 178.77% | -6.85% | |||
| Normalized Basic EPS | -25.43% | -3.35% | |||
| EPS Diluted | 178.77% | -6.85% | |||
| Normalized Diluted EPS | -25.43% | -3.35% | |||
| Average Basic Shares Outstanding | 0.02% | 0.02% | |||
| Average Diluted Shares Outstanding | 0.02% | 0.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||